Biased ligand modulation of seven transmembrane receptors (7TMRs): Functional implications for drug discovery

Journal of Medicinal Chemistry

Volumn 57, Issue 16, 2014, Pages 6887-6896

  Correll, Craig C ^a   McKittrick, Brian A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ARRESTIN; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; HCAR2 PROTEIN, HUMAN; LIGAND; MU OPIATE RECEPTOR; NICOTINIC RECEPTOR; RETINA S ANTIGEN;

AGONISTS; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; HUMAN; METABOLISM; PROCEDURES; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION;

ANIMALS; ARRESTINS; DRUG DISCOVERY; HUMANS; LIGANDS; PROTEIN CONFORMATION; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, DOPAMINE D2; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION;

EID: 84904492656     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401677g     Document Type: Review

References (83)

1. Bohn, L. Seeking ligand bias: assessing GPCR coupling to beta arrestins for drug discovery. Presented at the 243rd National Meeting of the American Chemical Society, 2012; MEDI-289.
2. DeFea, K. A. Beta arrestins: signal termination and transduction. Presented at the 243rd National Meeting of the American Chemical Society, 2012; MEDI-287.
3. Semple, G. Agonists of the nicotinic acid receptor (HCA2, GPR109a). Presented at the 243rd National Meeting of the American Chemical Society, 2012; MEDI-288.
4. Violin, J. D. Biased ligands as improved therapeutics: translating theory into drugs. Presented at the 243rd National Meeting of the American Chemical Society, 2012; MEDI-290.
5. Lagerstrom, M. C.; Schioth, H. B. Structural diversity of G protein-coupled receptors and significance for drug discovery Nat. Rev. Drug Discovery 2008, 7, 339-357
6. Heng, B. C.; Aubel, D.; Fussenegger, M. An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases Biotechnol. Adv. 2013, 31, 1676-1694
7. Rask-Andersen, M.; Almen, M. S.; Schioth, H. B. Trends in the exploitation of novel drug targets Nat. Rev. Drug Discovery 2011, 10, 579-590
8. Garland, S. L. Are GPCRs still a source of new targets? J. Biomol. Screening 2013, 33, 249-260
9. Lefkowitz, R. J. Historical review: a brief history and personal retrospective of seven-transmembrane receptors Trends Pharmacol. Sci. 2004, 25, 413-422
10. Lefkowitz, R. J.; Shenoy, S. K. Transduction of receptor signals by β-arrestins Science (Washington, DC, U. S.) 2005, 308, 512-517
11. Reiter, E.; Lefkowitz, R. J. GRKs and β-arrestins: roles in receptor silencing, trafficking and signaling Trends Endocrinol. Metab. 2006, 17, 159-165
12. Luttrell, L. M.; Gesty-Palmer, D. Beyond desensitization: physiological relevance of arrestin-dependent signaling Pharmacol Rev. 2010, 62, 305-330
13. Ribas, C.; Penela, P.; Murga, C.; Salcedo, A.; Garcia-Hoz, C.; Jurado-Pueyo, M.; Aymerich, I.; Mayor, F., Jr. The G protein-coupled receptor kinase (GRK) interactome: role of GRKs in GPCR regulation and signaling Biochim. Biophys. Acta 2007, 1768, 913-922
14. Bassoni, D. L.; Raab, W. J.; Achacoso, P. L.; Loh, C. Y.; Wehrman, T. S. Measurements of β-arrestin recruitment to activated seven transmembrane receptors using enzyme complementation Methods Mol. Biol. (N. Y., U. S.) 2012, 897, 181-203
15. Whalen, E. J.; Rajagopal, S.; Lefkowitz, R. J. Therapeutic potential of beta-arrestin- and G protein-biased agonists Trends Mol. Med. 2010, 17, 126-139
16. Kenakin, T. Agonist-receptor efficacy II: agonist trafficking of receptor signals Trends Pharmacol. Sci. 1995, 16, 232-238
17. Kenakin, T. Ligand-selective receptor conformations revisited: the promise and the problem Trends Pharmacol. Sci. 2003, 24, 346-354
18. Kenakin, T.; Christopoulos, A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact Nat. Rev. Drug Discovery 2013, 12, 205-216
19. Shenoy, S. K.; Lefkowitz, R. J. β-Arrestin-mediated receptor trafficking and signal transduction Trends Pharmacol. Sci. 2011, 32, 521-533
20. DeFea, K. A. Beta-arrestins as regulators of signal termination and transduction: How do they determine what to scaffold? Cell. Signalling 2011, 23, 621-629
21. Stallaert, W.; Christopoulos, A.; Bouvier, M. Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors Expert Opin. Drug Discovery 2011, 6, 811-825
22. Rajagopal, S. Quantifying biased agonism: understanding the links between affinity and efficacy Nat. Rev. Drug Discovery 2013, 12, 483
23. Rajagopal, S.; Ahn, S.; Rominger, D. H.; Gowen-MacDonald, W.; Lam, C. M.; Dewire, S. M.; Violin, J. D.; Lefkowitz, R. J. Quantifying ligand bias at seven-transmembrane receptors Mol. Pharmacol. 2011, 80, 367-377
24. Rajagopal, S.; Rajagopal, K.; Lefkowitz, R. J. Teaching old receptors new tricks: biasing seven-transmembrane receptors Nat. Rev. Drug Discovery 2010, 9, 373-386
25. Chen, X.; Sassano, M. F.; Zheng, L.; Setola, V.; Chen, M.; Bai, X.; Frye, S. V.; Wetsel, W. C.; Roth, B. L.; Jin, J. Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D2 receptor agonists J. Med. Chem. 2012, 55, 7141-7153
26. Lorenzen, A.; Stannek, C.; Lang, H.; Andrianov, V.; Kalvinsh, I.; Schwabe, U. Characterization of a G protein-coupled receptor for nicotinic acid Mol. Pharmacol. 2001, 59, 349-357
27. Wise, A.; Foord, S. M.; Fraser, N. J.; Barnes, A. A.; Elshourbagy, N.; Eilert, M.; Ignar, D. M.; Murdock, P. R.; Steplewski, K.; Green, A.; Brown, A. J.; Dowell, S. J.; Szekeres, P. G.; Hassall, D. G.; Marshall, F. H.; Wilson, S.; Pike, N. B. Molecular identification of high and low affinity receptors for nicotinic acid J. Biol. Chem. 2003, 278, 9869-9874
28. Tunaru, S.; Kero, J.; Schaub, A.; Wufka, C.; Blaukat, A.; Pfeffer, K.; Offermanns, S. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect Nat. Med. (N. Y., U. S.) 2003, 9, 352-355
29. Soga, T.; Kamohara, M.; Takasaki, J.; Matsumoto, S.-I.; Saito, T.; Ohishi, T.; Hiyama, H.; Matsuo, A.; Matsushime, H.; Furuichi, K. Molecular identification of nicotinic acid receptor Biochem. Biophys. Res. Commun. 2003, 303, 364-369
30. Semple, G.; Skinner, P. J.; Gharbaoui, T.; Shin, Y.-J.; Jung, J.-K.; Cherrier, M. C.; Webb, P. J.; Tamura, S. Y.; Boatman, P. D.; Sage, C. R.; Schrader, T. O.; Chen, R.; Colletti, S. L.; Tata, J. R.; Waters, M. G.; Cheng, K.; Taggart, A. K.; Cai, T.-Q.; Carballo-Jane, E.; Behan, D. P.; Connolly, D. T.; Richman, J. G. 3-(1 H -Tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice J. Med. Chem. 2008, 51, 5101-5108
31. Richman, J. G.; Kanemitsu-Parks, M.; Gaidarov, I.; Cameron, J. S.; Griffin, P.; Zheng, H.; Guerra, N. C.; Cham, L.; Maciejewski-Lenoir, D.; Behan, D. P.; Boatman, D.; Chen, R.; Skinner, P.; Ornelas, P.; Waters, M. G.; Wright, S. D.; Semple, G.; Connolly, D. T. Nicotinic acid receptor agonists differentially activate downstream effectors J. Biol. Chem. 2007, 282, 18028-18036
32. Boatman, P. D.; Lauring, B.; Schrader, T. O.; Kasem, M.; Johnson, B. R.; Skinner, P.; Jung, J.-K.; Xu, J.; Cherrier, M. C.; Webb, P. J.; Semple, G.; Sage, C. R.; Knudsen, J.; Chen, R.; Luo, W.-L.; Caro, L.; Cote, J.; Lai, E.; Wagner, J.; Taggart, A. K.; Carballo-Jane, E.; Hammond, M.; Colletti, S. L.; Tata, J. R.; Connolly, D. T.; Waters, M. G.; Richman, J. G. (1a R,5a R)1a,3,5,5a-Tetrahydro-1 H -2,3-diaza-cyclopropa[ a ]pentalene-4-carboxylic Acid (MK-1903): a potent GPR109a Agonist that lowers free fatty acids in humans J. Med. Chem. 2012, 55, 3644-3666
33. Palani, A.; Rao, A. U.; Chen, X.; Huang, X.; Su, J.; Tang, H.; Huang, Y.; Qin, J.; Xiao, D.; Degrado, S.; Sofolarides, M.; Zhu, X.; Liu, Z.; Cheewatrakoolpong, B.; Zhang, H.; Farley, C.; Cook, J.; Kurowski, S.; Li, Q.; van, H.; Margaret; Wang, G.; Hsieh, Y.; Li, F.; Greenfeder, S.; Chintala, M. Discovery of SCH 900271, a potent nicotinic acid receptor agonist for the treatment of dyslipidemia ACS Med. Chem. Lett. 2012, 3, 63-68
34. Lauring, B.; Taggart, A. K. P.; Tata, J. R.; Dunbar, R.; Caro, L.; Cheng, K.; Chin, J.; Colletti, S. L.; Cote, J.; Khalilieh, S.; Liu, J.; Luo, W.-L.; Maclean, A. A.; Peterson, L. B.; Polis, A. B.; Sirah, W.; Wu, T.-J.; Liu, X.; Jin, L.; Wu, K.; Boatman, P. D.; Semple, G.; Behan, D. P.; Connolly, D. T.; Lai, E.; Wagner, J. A.; Wright, S. D.; Cuffie, C.; Mitchel, Y. B.; Rader, D. J.; Paolini, J. F.; Waters, M. G.; Plump, A. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression Sci. Transl. Med. 2012, 4, 148-115
35. Boatman, P. D.; Richman, J. G.; Semple, G. Nicotinic acid receptor agonists J. Med. Chem. 2008, 51, 7653-7662
36. Walters, R. W.; Shukla, A. K.; Kovacs, J. J.; Violin, J. D.; DeWire, S. M.; Lam, C. M.; Chen, J. R.; Muehlbauer, M. J.; Whalen, E. J.; Lefkowitz, R. J. β-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice J. Clin. Invest. 2009, 119, 1312-1321
37. Thurmond, R. L.; Desai, P. J.; Dunford, P. J.; Fung-Leung, W.-P.; Hofstra, C. L.; Jiang, W.; Nguyen, S.; Riley, J. P.; Sun, S.; Williams, K. N.; Edwards, J. P.; Karlsson, L. A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties J. Pharmacol. Exp. Ther. 2004, 309, 404-413
38. Rosethorne, E. M.; Charlton, S. J. Agonist-biased signaling at the histamine H4 receptor: JNJ7777120 recruits β-arrestin without activating G proteins Mol. Pharmacol. 2011, 79, 749-757
39. Seifert, R.; Schneider, E. H.; Dove, S.; Brunskole, I.; Neumann, D.; Strasser, A.; Buschauer, A. Paradoxical stimulatory effects of the "standard" histamine H4-receptor antagonist JNJ7777120: the H4 receptor joins the club of 7 transmembrane domain receptors exhibiting functional selectivity Mol. Pharmacol. 2011, 79, 631-638
40. Nijmeijer, S.; Vischer, H. F.; Rosethorne, E. M.; Charlton, S. J.; Leurs, R. Analysis of multiple histamine H4 receptor compound classes uncovers Gαi protein- and β-arrestin2-biased ligands Mol. Pharmacol. 2012, 82, 1174-1182
41. Mowbray, C. E.; Bell, A. S.; Clarke, N. P.; Collins, M.; Jones, R. M.; Lane, C. A. L.; Liu, W. L.; Newman, S. D.; Paradowski, M.; Schenck, E. J.; Selby, M. D.; Swain, N. A.; Williams, D. H. Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist Bioorg. Med. Chem. Lett. 2011, 21, 6596-6602
42. Salcedo, C.; Pontes, C.; Merlos, M. Is the H4 receptor a new drug target for allergies and asthma? Front. Biosci., Elite Ed. 2013, E5, 178-187
43. Bohn, L. M.; Lefkowitz, R. J.; Gainetdinov, R. R.; Peppel, K.; Caron, M. G.; Lin, F. T. Enhanced morphine analgesia in mice lacking beta-arrestin 2 Science 1999, 286, 2495-2498
44. Li, Y.; Liu, X.; Liu, C.; Kang, J.; Yang, J.; Pei, G.; Wu, C. Improvement of morphine-mediated analgesia by inhibition of β-arrestin 2 expression in mice periaqueductal gray matter Int. J. Mol. Sci. 2009, 10, 954-963
45. Yang, C.-H.; Huang, H.-W.; Chen, K.-H.; Chen, Y.-S.; Sheen-Chen, S.-M.; Lin, C.-R. Antinociceptive potentiation and attenuation of tolerance by intrathecal β-arrestin 2 small interfering RNA in rats Br. J. Anaesth. 2011, 107, 774-781
46. Bohn, L. M.; Lefkowitz, R. J.; Caron, M. G. Differential mechanisms of morphine antinociceptive tolerance revealed in β-arrestin-2 knock-out mice J. Neurosci. 2002, 22, 10494-10500
47. 4-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence Nature (London) 2000, 408, 720-723
48. Raehal, K. M.; Walker, J. K.; Bohn, L. M. Morphine side effects in beta-arrestin 2 knockout mice J. Pharmacol. Exp. Ther. 2005, 314, 1195-1201
49. Groer, C. E.; Tidgewell, K.; Moyer, R. A.; Harding, W. W.; Rothman, R. B.; Prisinzano, T. E.; Bohn, L. M. An opioid agonist that does not induce mu-opioid receptor-arrestin interactions or receptor internalization Mol. Pharmacol. 2007, 71, 549-557
50. Tidgewell, K.; Groer, C. E.; Harding, W. W.; Lozama, A.; Schmidt, M.; Marquam, A.; Hiemstra, J.; Partilla, J. S.; Dersch, C. M.; Rothman, R. B.; Bohn, L. M.; Prisinzano, T. E. Herkinorin analogues with differential beta-arrestin-2 interactions J. Med. Chem. 2008, 51, 2421-2431
51. Soergel, D. G.; Subach, R. A.; Sadler, B.; Connell, J.; Marion, A. S.; Cowan, C.; Violin, J. D.; Lark, M. W. First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers J. Clin. Pharmacol. 2013, 53, 892-899
52. Trevena presents first-in-man study results for mu-opioid biased ligand TRV130. http://www.trevenainc.com/news-details.php?id=48, 2013.
53. Holloway, A. C.; Qian, H.; Pipolo, L.; Ziogas, J.; Miura, S.-I.; Karnik, S.; Southwell, B. R.; Lew, M. J.; Thomas, W. G. Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors Mol. Pharmacol. 2002, 61, 768-777
54. Feng, Y.-H.; Noda, K.; Saad, Y.; Liu, X.-p.; Hasain, A.; Karnik, S. S. The docking of Arg2 of angiotensin II with Asp281 of AT1 receptor is essential for full agonism J. Biol. Chem. 1995, 270, 12846-12850
55. Noda, K.; Feng, Y.-H.; Liu, X.-p.; Saad, Y.; Husain, A.; Karnik, S. S. The active state of the AT1 angiotensin receptor is generated by angiotensin II induction Biochemistry 1996, 35, 16435-16442
56. Wei, H.; Ahn, S.; Shenoy, S. K.; Karnik, S. S.; Hunyady, L.; Luttrell, L. M.; Lefkowitz, R. J. Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2 Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 10782-10787
57. Ahn, S.; Shenoy, S. K.; Wei, H.; Lefkowitz, R. J. Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor J. Biol. Chem. 2004, 279, 35518-35525
58. Rajagopal, K.; Whalen, E. J.; Violin, J. D.; Stiber, J. A.; Rosenberg, P. B.; Premont, R. T.; Coffman, T. M.; Rockman, H. A.; Lefkowitz, R. J. Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 16284-16289
59. Aplin, M.; Christensen, G. L.; Schneider, M.; Heydorn, A.; Gammeltoft, S.; Kjoelbye, A. L.; Sheikh, S. P.; Hansen, J. L. The angiotensin type 1 receptor activates extracellular signal-regulated kinases 1 and 2 by G protein-dependent and -independent pathways in cardiac myocytes and Langendorff-perfused hearts Basic Clin. Pharmacol. Toxicol. 2007, 100, 289-295
60. Aplin, M.; Christensen, G. L.; Schneider, M.; Heydorn, A.; Gammeltoft, S.; Kjoelbye, A. L.; Sheikh, S. P.; Hansen, J. L. Differential extracellular signal-regulated kinases 1 and 2 activation by the angiotensin type 1 receptor supports distinct phenotypes of cardiac myocytes Basic Clin. Pharmacol. Toxicol. 2007, 100, 296-301
61. Violin, J. D.; DeWire, S. M.; Yamashita, D.; Rominger, D. H.; Nguyen, L.; Schiller, K.; Whalen, E. J.; Gowen, M.; Lark, M. W. Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance J. Pharmacol. Exp. Ther. 2010, 335, 572-579
62. Soergel, D. G.; Subach, R. A.; Cowan, C. L.; Violin, J. D.; Lark, M. W. First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers J. Clin. Pharmacol. 2013, 53, 892-899
63. Soergel, D. G.; Subach, R. A.; James, I. E.; Cowan, C. L.; Gowen, M.; Lark, M. W. TRV027, a beta-arrestin biased ligand at the angiotensin 2 type 1 receptor, produces rapid, reversible changes in hemodynamics in patients with stable systolic heart failure J. Am. Coll. Cardiol. 2013, 61, E683
64. Violin, J. D.; Soergel, D. G.; Boerrigter, G.; Burnett, J. C. J.; Lark, M. W. GPCR biased ligands as novel heart failure therapeutics Trends Cardiovasc. Med. 2013, 23, 242-249
65. Boerrigter, G.; Lark, M. W.; Whalen, E. J.; Soergel, D. G.; Violin, J. D.; Burnett, J. C. J. Cardiorenal actions of TRV120027, a novel β-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure Circ.: Heart Failure 2011, 4, 770-778
66. Lefkowitz, R. J. A brief history of G-protein coupled receptors (Nobel Lecture) Angew. Chem., Int. Ed. 2013, 52, 6366-6378
67. Wisler, J. W.; DeWire, S. M.; Whalen, E. J.; Violin, J. D.; Drake, M. T.; Ahn, S.; Shenoy, S. K.; Lefkowitz, R. J. A unique mechanism of β-blocker action: carvedilol stimulates β-arrestin signaling Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 16657-16662
68. Kim, I.-M.; Tilley, D. G.; Chen, J.; Salazar, N. C.; Whalen, E. J.; Violin, J. D.; Rockman, H. A. β-Blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivation Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 14555-14560
69. Nakaya, M.; Chikura, S.; Watari, K.; Mizuno, N.; Mochinaga, K.; Mangmool, S.; Koyanagi, S.; Ohdo, S.; Sato, Y.; Ide, T.; Nishida, M.; Kurose, H. Induction of cardiac fibrosis by β-blocker in G protein-independent and G protein-coupled receptor kinase 5/β-arrestin2-dependent signaling pathways J. Biol. Chem. 2012, 287, 669-35677
70. Drake, M. T.; Violin, J. D.; Whalen, E. J.; Wisler, J. W.; Shenoy, S. K.; Lefkowitz, R. J. β-Arrestin-biased agonism at the β2-adrenergic receptor J. Biol. Chem. 2008, 283, 5669-5676
71. Barisione, G.; Baroffio, M.; Crimi, E.; Brusasco, V. Beta-adrenergic agonists Pharmaceuticals 2010, 3, 1016-1044
72. Cazzola, M.; Page, C. P.; Calzetta, L.; Matera, M. G. Pharmacology and therapeutics of bronchodilators Pharmacol. Rev. 2012, 64, 450-504
73. Deshpande, D. A.; Theriot, B. S.; Penn, R. B.; Walker, J. K. L. β-Arrestins specifically constrain β2-adrenergic receptor signaling and function in airway smooth muscle FASEB J. 2008, 22, 2134-2141
74. Wang, W. C. H.; Mihlbachler, K. A.; Brunnett, A. C.; Liggett, S. B. Targeted transgenesis reveals discrete attenuator functions of GRK and PKA in airway β2-adrenergic receptor physiologic signaling Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 15007-15012
75. Carter, A. A.; Hill, S. J. Characterization of isoprenaline- and salmeterol-stimulated interactions between beta2-adrenoceptors and beta-arrestin 2 using beta-galactosidase complementation in C2C12 cells J. Pharmacol. Exp. Ther. 2005, 315, 839-848
76. Reiner, S.; Ambrosio, M.; Hoffmann, C.; Lohse, M. J. Differential signaling of the endogenous agonists at the beta2-adrenergic receptor J. Biol. Chem. 2010, 285, 36188-36198
77. Nobles, K. N.; Xiao, K.; Ahn, S.; Shukla, A. K.; Lam, C. M.; Rajagopal, S.; Strachan, R. T.; Huang, T. Y.; Bressler, E. A.; Hara, M. R.; Shenoy, S. K.; Gygi, S. P.; Lefkowitz, R. J. Distinct phosphorylation sites on the beta(2)-adrenergic receptor establish a barcode that encodes differential functions of beta-arrestin Sci. Signaling 2011, 4, ra51
78. Kahsai, A. W.; Xiao, K.; Rajagopal, S.; Ahn, S.; Shukla, A. K.; Sun, J.; Oas, T. G.; Lefkowitz, R. J. Multiple ligand-specific conformations of the beta2-adrenergic receptor Nat. Chem. Biol. 2012, 7, 692-700
79. Zhang, R.; Xie, X. Tools for GPCR drug discovery Acta Pharmacol. Sin. 2011, 33, 372-384
80. Venkatakrishnan, A. J.; Deupi, X.; Lebon, G.; Tate, C. G.; Schertler, G. F.; Babu, M. M. Molecular signatures of G-protein-coupled receptors Nature 2013, 494, 185-194
81. Hamdan, F. F.; Audet, M.; Garneau, P.; Pelletier, J.; Bouvier, M. High-throughput screening of G protein-coupled receptor antagonists using a bioluminescence resonance energy transfer 1-based β-arrestin2 recruitment assay J. Biomol. Screening 2005, 10, 463-475
82. Ramsay, D.; Kellett, E.; McVey, M.; Rees, S.; Milligan, G. Homo- and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences Biochem. J. 2002, 365, 429-440
83. Angers, S.; Salahpour, A.; Joly, E.; Hilairet, S.; Chelsky, D.; Dennis, M.; Bouvier, M. Detection of β-2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET) Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 3684-3689